Warfarin and other anticoagulants – monitoring of patients during the COVID-19 pandemic

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) issued this guidance following reports from King’s College Hospital regarding a surge in patients experiencing dangerously high anticoagulation levels during the COVID-19 pandemic. This trend, primarily observed in patients using warfarin, significantly increases the risk of life-threatening bleeding. The complications are attributed to multiple factors: the physiological impact of COVID-19 infection, concurrent antibiotic treatments, and lifestyle changes during lockdowns, such as restricted access to specific vegetables and increased alcohol consumption. Additionally, safety incidents occurred where patients inadvertently continued warfarin after starting new direct-acting oral anticoagulants (DOACs). Under the regulatory framework for medicine safety and NICE guidelines, the MHRA advises healthcare providers to maintain rigorous monitoring for patients with suspected or confirmed COVID-19. Professionals must remain vigilant regarding drug-drug interactions between anticoagulants and the antiviral or antibiotic therapies used in pandemic-related care. Crucially, clinical teams must ensure warfarin treatment is fully discontinued before initiating DOACs such as apixaban or rivaroxaban. Patients are encouraged to report symptoms of illness, dietary changes, or new supplements to their healthcare providers immediately to allow for timely dose adjustments. These proactive measures are essential to mitigate the heightened risk of over-anticoagulation and ensure patient safety during periods of acute illness or social disruption.